RecruitingOBSERVATIONAL

Weight Loss in Adults Using Semaglutide (Real-world Study)

This study, called 'Weight Loss in Adults Using Semaglutide,' is designed to understand how well a medication called semaglutide helps people lose weight. It's a 'real-world study,' meaning it observes how this treatment works when doctors prescribe it in their day-to-day practice, rather than in a highly controlled research environment. The main goal is to see how much weight people lose when taking semaglutide for being overweight or obese. Participants will be adults aged 18 or older who are starting semaglutide for weight management and meet specific health criteria, such as their body mass index (BMI). The study avoids people with diabetes, previous weight-loss surgery, or those who have used similar medications before. It aims to provide practical information on semaglutide's effectiveness in typical UK healthcare settings.

At a glance

Status

Recruiting

Sponsor

Novo Nordisk A/S

Enrolment target

35,000

Start

12 May 2026

Estimated completion

01 Jun 2026

Overweight Obesity

What is this study about?

This study is called 'Weight Loss in Adults Using Semaglutide' and it's looking into how a medication called semaglutide helps people lose weight. Semaglutide is a medicine that some doctors can prescribe to help with weight management. This isn't a typical trial where doctors are told exactly how to treat patients; instead, they prescribe the medication as they usually would in their practice. The main aim is to see how much weight people actually lose when they start taking semaglutide for being overweight or obese.

The researchers want to gather information from people in a 'real-world' setting. This means they are observing how the treatment works in regular doctor's visits and daily life, rather than in a very strict research environment. This approach can help us understand how effective semaglutide is for a wider range of people, and how it fits into normal healthcare.

Understanding how well semaglutide works in everyday clinics is really important. The information from this study could help doctors and patients make better decisions about weight management options. It also helps healthcare providers understand the medication's impact on people who are overweight or obese in a practical way.

Key takeaways

This study is observing how semaglutide helps adults lose weight in everyday clinical practice.
It's for adults aged 18 or over who are starting semaglutide for weight management.
Participants must be overweight with related health issues, or obese.
You cannot join if you have diabetes, have had weight-loss surgery, or previously used similar weight-loss drugs.
Participation involves no extra steps; your doctor treats you as usual.
The study helps understand semaglutide's effectiveness in real-life settings.

Who may be eligible?

To be part of this study, you need to be an adult, aged 18 or older, and your doctor must be starting you on semaglutide specifically for weight management. Your body mass index (BMI) needs to be 30 or higher (which is considered obese), or your BMI needs to be between 27 and 30 (considered overweight) with at least one weight-related health issue. The study will also have some other general health requirements.

You cannot join if you have previously used medications called GLP-1 RAs (which semaglutide is part of) or other medicines specifically for weight management. Also, if you’ve had weight-loss surgery, have diabetes, or are pregnant at the start of the study, you won't be able to take part.

These rules ensure that the study includes people who are starting semaglutide for the first time for weight loss and helps researchers focus on how the medicine works in this specific group.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Is your doctor starting you on semaglutide for weight loss?
Is your Body Mass Index (BMI) 30 or higher, or between 27 and 30 with a weight-related health problem?
Have you never used a GLP-1 RA medication (like semaglutide) or other weight-loss medicines before?
Have you never had weight-loss surgery?
Do you not have diabetes and are you not pregnant?

Answer every question to see your result.

What does participation involve?

This study is a 'real-world study,' which means you would be receiving semaglutide as part of your usual healthcare, as decided by your doctor. You wouldn't be doing anything extra specifically for the study that you wouldn't normally do if you were prescribed this medication. You will receive your medication from your doctor, and they will monitor your progress and health as they usually would. There aren't any special study visits or extra tests beyond what your doctor deems necessary for your treatment. The study will collect information from your routine medical records over a period, but it doesn't involve any additional steps for you.

Potential risks and benefits

Participating means you would be taking semaglutide for weight management, which could lead to significant weight loss and potentially improve weight-related health conditions. As with any medication, semaglutide has potential side effects, which your doctor will discuss with you. These commonly include nausea, vomiting, diarrhoea, or constipation. This study primarily observes what happens in routine care, so there are no extra risks beyond those associated with taking the prescribed medication itself. You maintain the right to withdraw from treatment at any point, just as you would with any other prescribed medication.

Locations (2)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

Novo Nordisk Investigational Site
Verified postcode
Seattle, United States· Recruiting
Novo Nordisk Investigational Site
Verified postcode
London, United Kingdom· Recruiting

Common questions

What is semaglutide?

Semaglutide is a medication that can help people lose weight, often prescribed when lifestyle changes haven't been enough. It works to reduce appetite and help you feel full.

Is this a new medication?

Semaglutide is already approved and available for use in the UK. This study is looking at how it helps people in real-life doctor's practices.

Will I have to do anything differently if I join this study?

No, this study simply collects information from people who are already being prescribed semaglutide by their doctor. You won't have extra visits or tests just for the study.

What does 'real-world study' mean?

It means the study observes how a treatment works in regular doctor's visits and daily life, rather than in a highly controlled research environment. Doctors prescribe the medicine as they usually would.

Can I still join if I have diabetes?

No, people with diabetes at the start of the study are not able to participate in this particular research.

How to find out more

Novo Nordisk

clinicaltrials@novonordisk.com (+1) 866-867-7178 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.